N.E.W. Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

N.E.W. Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13	Closed	-$1.38K	–	857
2025 Q2	$1.38K	Hold	13	–	–	﹤0.01%	769
2025 Q1	$1.61K	Buy	+13	New	+$1.7K	﹤0.01%	807

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

N.E.W. Advisory Services's JAZZ Position: Q3 2025 in Review

N.E.W. Advisory Services sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 13 shares — an estimated $1.38K sold.

N.E.W. Advisory Services first reported a position in JAZZ in Q1 2025 and held it in 2 quarters. The position peaked at $1.61K in Q1 2025. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

N.E.W. Advisory Services reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
N.E.W. Advisory Services sold 13 Jazz Pharmaceuticals shares in Q3 2025, an estimated $1.38K.
N.E.W. Advisory Services first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 2 quarters.
N.E.W. Advisory Services's Jazz Pharmaceuticals position peaked at $1.61K in Q1 2025.
503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on N.E.W. Advisory Services's 13F filing for Q3 2025, filed 27 Oct 2025.